Sonoma Pharmaceuticals, Inc. (SNOA)
USD 3.38
(-4.52%)
USD 3.38
(-4.52%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 8.75 Million USD | 4.23% |
| 2023 | 8.25 Million USD | -18.66% |
| 2022 | 10.14 Million USD | 5.44% |
| 2021 | 9.62 Million USD | 64.34% |
| 2020 | 5.85 Million USD | 47.92% |
| 2019 | 3.95 Million USD | 2.04% |
| 2018 | 3.88 Million USD | -3.67% |
| 2017 | 4.02 Million USD | 9.96% |
| 2016 | 3.66 Million USD | 22.34% |
| 2015 | 2.99 Million USD | -65.7% |
| 2014 | 8.72 Million USD | 2.88% |
| 2013 | 8.48 Million USD | -2.55% |
| 2012 | 8.7 Million USD | 25.03% |
| 2011 | 6.96 Million USD | 119.45% |
| 2010 | 3.17 Million USD | -0.16% |
| 2009 | 3.17 Million USD | -61.17% |
| 2008 | 8.18 Million USD | -32.08% |
| 2007 | 12.04 Million USD | 125.17% |
| 2006 | 5.35 Million USD | 12.94% |
| 2005 | 4.73 Million USD | 0.0% |
| 2003 | 1.04 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.96 Million USD | -7.99% |
| 2024 Q3 | 7.92 Million USD | -0.43% |
| 2024 Q4 | 8.75 Million USD | 10.47% |
| 2024 FY | 8.75 Million USD | 6.08% |
| 2024 Q1 | 8.65 Million USD | 4.81% |
| 2023 FY | 8.25 Million USD | -18.66% |
| 2023 Q3 | 8.36 Million USD | 5.39% |
| 2023 Q2 | 7.94 Million USD | -13.68% |
| 2023 Q4 | 8.25 Million USD | -1.37% |
| 2023 Q1 | 9.19 Million USD | -9.35% |
| 2022 FY | 10.14 Million USD | 5.44% |
| 2022 Q4 | 10.14 Million USD | 24.09% |
| 2022 Q3 | 8.17 Million USD | -2.27% |
| 2022 Q2 | 8.36 Million USD | -11.92% |
| 2022 Q1 | 9.5 Million USD | -1.29% |
| 2021 Q3 | 5.91 Million USD | -10.15% |
| 2021 Q2 | 6.58 Million USD | -9.1% |
| 2021 FY | 9.62 Million USD | 64.34% |
| 2021 Q1 | 7.24 Million USD | 23.67% |
| 2021 Q4 | 9.62 Million USD | 62.7% |
| 2020 Q3 | 5.28 Million USD | -9.99% |
| 2020 FY | 5.85 Million USD | 47.92% |
| 2020 Q1 | 5.41 Million USD | 36.75% |
| 2020 Q4 | 5.85 Million USD | 10.76% |
| 2020 Q2 | 5.87 Million USD | 8.5% |
| 2019 Q3 | 3.7 Million USD | 3.99% |
| 2019 FY | 3.95 Million USD | 2.04% |
| 2019 Q1 | 4 Million USD | 3.2% |
| 2019 Q2 | 3.56 Million USD | -11.01% |
| 2019 Q4 | 3.95 Million USD | 6.86% |
| 2018 Q2 | 3.99 Million USD | 4.67% |
| 2018 FY | 3.88 Million USD | -3.67% |
| 2018 Q4 | 3.88 Million USD | -5.34% |
| 2018 Q3 | 4.09 Million USD | 2.65% |
| 2018 Q1 | 3.81 Million USD | -5.29% |
| 2017 FY | 4.02 Million USD | 9.96% |
| 2017 Q4 | 4.02 Million USD | -13.26% |
| 2017 Q3 | 4.64 Million USD | 45.03% |
| 2017 Q2 | 3.2 Million USD | -10.31% |
| 2017 Q1 | 3.57 Million USD | -2.54% |
| 2016 FY | 3.66 Million USD | 22.34% |
| 2016 Q2 | 2.83 Million USD | -7.59% |
| 2016 Q1 | 3.06 Million USD | 2.51% |
| 2016 Q3 | 2.98 Million USD | 5.08% |
| 2016 Q4 | 3.66 Million USD | 22.92% |
| 2015 Q3 | 4 Million USD | -20.26% |
| 2015 Q2 | 5.02 Million USD | -22.41% |
| 2015 Q1 | 6.47 Million USD | -25.81% |
| 2015 Q4 | 2.99 Million USD | -25.26% |
| 2015 FY | 2.99 Million USD | -65.7% |
| 2014 Q2 | 7.33 Million USD | -7.94% |
| 2014 Q4 | 8.72 Million USD | 35.4% |
| 2014 Q1 | 7.96 Million USD | -6.13% |
| 2014 Q3 | 6.44 Million USD | -12.08% |
| 2014 FY | 8.72 Million USD | 2.88% |
| 2013 Q1 | 9.35 Million USD | 7.41% |
| 2013 Q4 | 8.48 Million USD | -2.51% |
| 2013 Q3 | 8.7 Million USD | -37.36% |
| 2013 Q2 | 13.89 Million USD | 48.57% |
| 2013 FY | 8.48 Million USD | -2.55% |
| 2012 Q1 | 8.82 Million USD | 26.71% |
| 2012 FY | 8.7 Million USD | 25.03% |
| 2012 Q4 | 8.7 Million USD | -1.27% |
| 2012 Q3 | 8.81 Million USD | 11.63% |
| 2012 Q2 | 7.89 Million USD | -10.47% |
| 2011 FY | 6.96 Million USD | 119.45% |
| 2011 Q4 | 6.96 Million USD | 22.29% |
| 2011 Q3 | 5.69 Million USD | 19.72% |
| 2011 Q1 | 4.82 Million USD | 52.19% |
| 2011 Q2 | 4.75 Million USD | -1.51% |
| 2010 Q2 | 3.78 Million USD | -23.38% |
| 2010 Q4 | 3.17 Million USD | 5.35% |
| 2010 Q3 | 3.01 Million USD | -20.34% |
| 2010 FY | 3.17 Million USD | -0.16% |
| 2010 Q1 | 4.93 Million USD | 55.29% |
| 2009 Q2 | 4.7 Million USD | -13.34% |
| 2009 Q4 | 3.17 Million USD | -20.37% |
| 2009 FY | 3.17 Million USD | -61.17% |
| 2009 Q1 | 5.42 Million USD | -33.7% |
| 2009 Q3 | 3.99 Million USD | -15.12% |
| 2008 Q1 | 10.93 Million USD | -9.21% |
| 2008 Q2 | 6.64 Million USD | -39.29% |
| 2008 Q3 | 6.61 Million USD | -0.44% |
| 2008 Q4 | 8.18 Million USD | 23.77% |
| 2008 FY | 8.18 Million USD | -32.08% |
| 2007 FY | 12.04 Million USD | 125.17% |
| 2007 Q3 | 11.83 Million USD | 30.29% |
| 2007 Q2 | 9.08 Million USD | 0.0% |
| 2007 Q4 | 12.04 Million USD | 1.83% |
| 2006 Q4 | 5.35 Million USD | 0.0% |
| 2006 FY | 5.35 Million USD | 12.94% |
| 2005 Q4 | 4.73 Million USD | 0.0% |
| 2005 FY | 4.73 Million USD | 0.0% |
| 2003 FY | 1.04 Million USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.675% |
| Theratechnologies Inc. | 98.63 Million USD | 91.123% |
| Safety Shot Inc | 3.89 Million USD | -124.972% |
| Cosmos Health Inc. | 30.25 Million USD | 71.057% |
| Cronos Group Inc. | 43.73 Million USD | 79.98% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 98.929% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 81.926% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 95.172% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 36.34% |
| ProPhase Labs, Inc. | 42.54 Million USD | 79.419% |
| Dynavax Technologies Corporation | 375.02 Million USD | 97.665% |
| Radius Health, Inc. | 804.29 Million USD | 98.911% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 4.791% |
| Alvotech | 1.88 Billion USD | 99.535% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -42.615% |
| Alpha Teknova, Inc. | 38.55 Million USD | 77.287% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 93.603% |
| SCYNEXIS, Inc. | 55.45 Million USD | 84.209% |
| Harrow Health, Inc. | 241.75 Million USD | 96.378% |
| Biofrontera Inc. | 23.13 Million USD | 62.159% |
| DURECT Corporation | 30.4 Million USD | 71.203% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.204% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.144% |
| OptiNose, Inc. | 194.33 Million USD | 95.494% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 58.261% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 94.658% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 83.327% |
| SIGA Technologies, Inc. | 57.97 Million USD | 84.898% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 96.016% |
| Shineco, Inc. | 47.6 Million USD | 81.606% |
| Phibro Animal Health Corporation | 725.54 Million USD | 98.793% |
| Procaps Group S.A. | 462.06 Million USD | 98.105% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 37.555% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -3888.848% |
| Viatris Inc. | 27.21 Billion USD | 99.968% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -42.615% |
| Rockwell Medical, Inc. | 30.88 Million USD | 71.647% |
| Incannex Healthcare Limited | 5.83 Million USD | -50.189% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 90.312% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.019% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.076% |
| PetIQ, Inc. | 645.22 Million USD | 98.643% |
| Silver Spike Investment Corp. | 3 Million USD | -190.913% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.141% |
| Journey Medical Corporation | 56.49 Million USD | 84.502% |
| Alimera Sciences, Inc. | 107.35 Million USD | 91.844% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 58.922% |
| Assertio Holdings, Inc. | 148.41 Million USD | 94.1% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -361.823% |
| Embecta Corp. | 2.03 Billion USD | 99.57% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -3.127% |
| Procaps Group, S.A. | 462.06 Million USD | 98.105% |
| PainReform Ltd. | 2.69 Million USD | -225.381% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 94.95% |
| Hempacco Co., Inc. | 18.82 Million USD | 53.481% |
| Talphera, Inc. | 6.29 Million USD | -39.205% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 98.757% |
| Alvotech | 1.88 Billion USD | 99.535% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 98.952% |
| Kamada Ltd. | 109.96 Million USD | 92.038% |
| Indivior PLC | 1.95 Billion USD | 99.551% |
| Currenc Group, Inc. | 177.67 Million USD | 95.072% |
| Evoke Pharma, Inc. | 9.64 Million USD | 9.246% |
| Flora Growth Corp. | 17.22 Million USD | 49.158% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -3.127% |
| Evolus, Inc. | 209.68 Million USD | 95.824% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.368% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 98.998% |
| Akanda Corp. | 12.66 Million USD | 30.886% |